American Journal of Infection Control

The Centers for Disease Control and Prevention estimates that on any given day, about 1 in 31 hospitalized patients has at least 1 hospital-associated infection (HAI).1 This translates to approximately three-quarters of a million HAIs in U.S. acute

There is a growing awareness of the hospital environment as a reservoir for multidrug-resistant organisms and other pathogens that can lead to the development of healthcare-associated infections. Clostridioides difficile(C. difficile) spores are

SARS-CoV-2, the virus that causes COVID-19 disease was first discovered in China in December, 2019. The disease quickly spread globally, with the first U.S. case identified in January, 2020.1 It was officially declared a pandemic on March 11, 2020

The global COVID-19 pandemic continues to create unprecedented demands for respiratory protection for health care personnel (HCP). This demand has forced HCP to utilize respirators they might not normally use in an effort to protect themselves

Coronavirus disease 2019 (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has globally spread and been declared as a pandemic by the World Health Organization on March 11, 2020.1 COVID-19 has been spreading

As of August 9th 2020, nearly 20 million individuals contracted COVID-19 and about 720,000 died.1 The United States counts for one fourth of these cases. SARS-CoV-2 transmission occurs principally through respiratory droplets or direct contact.2

The immunocompromised condition of children with cancer places them at high risk of infection acquistion.1 Bacteria account for a considerable percentage of these infections and are associated with substantial morbidity and mortality.1 The impact of

Candida auris presents a unique challenge to practitioners and infection control teams worldwide because of its virulence, alarming resistance profile, environmental fitness, and risk of nosocomial transmission. We describe two cases of Candida auris

Over 85% of human antibiotic use worldwide occurs in outpatient settings including emergency departments (ED)s and urgent acre clinics (UCC)s.1 The most common diagnoses leading to outpatient antibiotic prescriptions are undoubtedly acute respiratory

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus causing coronavirus disease 2019 (COVID-19), was initially described in Wuhan, China in late 2019.1 Infection with SARS-CoV-2 typically causes fever, cough, and